LNTH Q3 2024 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$379M+18.4% YoY

Gross Profit

$242M63.9% margin

Operating Income

$134M35.3% margin

Net Income

$131M34.6% margin

EPS (Diluted)

$1.79

QoQ Revenue Growth

-3.9%

Cash Flow

Operating Cash Flow

$175M

Free Cash Flow

$159M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$870M

Stockholders' Equity

$1.2B

Cash & Equivalents

$866M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379M	$320M	+18.4%
Gross Profit	$242M	$200M	+21.1%
Operating Income	$134M	$112M	+19.0%
Net Income	$131M	$132M	-0.7%

Revenue Segments

Product

$375M33%

PYLARIFY

$260M23%

Radiopharmaceutical Oncology

$260M23%

Total Precision Diagnostics

$104M9%

DEFINITY

$77M7%

Techne Lite

$20M2%

Strategic Partnerships And Other

$15M1%

Other Precision Diagnostics

$6M1%

License and Royalty Revenues

$4M0%